Future research directions should focus on elucidating the mechanistic pathways through which these S100 proteins interact with immune cells, potentially leading to novel therapeutic strategies targeting immune responses in TB (Gonzalez et al., 2020; Donato et al., 2013). This evidence concerns the gene S100A1 and tuberculosis.